Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro.

Acta Pharmacologica Sinica
Juan JinYu-jing Wu

Abstract

To investigate the effects of (-)-epigallocatechin-3-gallate (EGCG), an active compound in green tea, on prostaglandin E(2) (PGE(2))-induced proliferation and migration, and the expression of prostanoid EP(1) receptors in hepatocellular carcinoma (HCC) cells. HCC cell line HepG2, human hepatoma cell lines MHCC-97L, MHCC-97H and human hepatocyte cell line L02 were used. Cell viability was analyzed using MTT assay. PGE(2) production was determined with immunoassay. Wound healing assay and transwell filter assay were employed to assess the extent of HCC cell migration. The expression of EP(1) receptor and Gq protein were examined using Western blot assay. PGE(2) (4-40000 nmol/L) or the EP(1) receptor agonist ONO-DI-004 (400-4000 nmol/L) increased the viability and migration of HepG2 cells in concentration-dependent manners. EGCG (100 μg/mL) significantly inhibited the viability and migration of HepG2 cells induced by PGE(2) or ONO-DI-004. HepG2 cells secreted an abundant amount of PGE(2) into the medium, and EGCG (100 μg/mL) significantly inhibited the PGE(2)production and EP(1) receptor expression in HepG2 cells. EGCG (100 μg/mL) also inhibited the viability of MHCC-97L cells, but not that of MHCC-97H cells. Both EGCG (100 μg/mL)...Continue Reading

References

Mar 30, 2001·The Journal of Biological Chemistry·C H LiuT Hla
Sep 3, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yao-Ping LuAllan H Conney
Aug 27, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jing LengTong Wu
Oct 2, 2003·The Journal of Nutrition·Balz Frei, Jane V Higdon
Jul 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gianfranco FassinaAdriana Albini
Sep 2, 2004·Virchows Archiv : an International Journal of Pathology·Dominique WendumJean-François Fléjou
Nov 27, 2004·Carcinogenesis·Toshihiko KawamoriKeiji Wakabayashi
Apr 23, 2005·Cancer Biology & Therapy·Yoshiro Niitsu
Jan 19, 2006·The Journal of Investigative Dermatology·Kathleen L ToberTatiana M Oberyszyn
May 3, 2006·Molecular Carcinogenesis·Chung S YangXinpei Hao
Oct 6, 2007·International Journal of Cancer. Journal International Du Cancer·Marco BreinigMichael André Kern
Mar 3, 2009·Annals of the New York Academy of Sciences·Antonella CusimanoMelchiorre Cervello
Oct 26, 2010·Medical Hypotheses·V Sánchez-HuertaJ Flores-Estrada

❮ Previous
Next ❯

Citations

Sep 22, 2012·Seminars in Immunopathology·Masako Nakanishi, Daniel W Rosenberg
Dec 25, 2012·Biochemical Pharmacology·Stephanie C Tucker, Kenneth V Honn
Feb 10, 2016·BioMed Research International·Chen-Yi LiaoWu-Hsien Kuo
Jan 8, 2013·Nutrition·Undurti N Das
Aug 7, 2017·Oncology Letters·Elena Díaz-RodríguezAtanasio Pandiella
Aug 11, 2018·Cancer Metastasis Reviews·Dali TongJun Jiang
May 8, 2018·International Journal of Molecular Sciences·Wen-Ting PengWei Wei
Sep 16, 2020·Biochemistry·Malak AlannanAksam Merched

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.